Good day, and thank you for standing by. Welcome to ALS Limited H1 FY '26 results briefing. [Operator Instructions]. Please be advised that today's conference is being recorded. I would now like to ...

ALS Ltd (CPBLF) reports a 10.7% revenue increase and a 19.3% rise in underlying EBIT, while overcoming integration and market challenges.

Earnings call ALS Limited delivered strong H1 FY26 results with revenue up 13.3% YoY to AUD 1.7 billion and underlying EBIT up 14.7% to AUD 287.2 million, driven by broad-based organic growth and ...

ALS Ltd. has reported its financial results for the first half of fiscal year 2025, highlighting changes in its investment in Nuvisan, moving from a 49% to a 100% consolidated stake. The company’s ...

In a report released today, Nathan Reilly from UBS maintained a Hold rating on ALS Ltd. (CPBLF – Research Report), with a price target of A$13.30. The company’s shares closed last Wednesday at $8.51.

Unlock your investing potential with TipRanks Premium - Now At 40% OFF! Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter ALS Ltd. announces a change in ...

ALS Limited has confirmed a malicious cyber incident involving unauthorised third-party access to its IT systems, causing temporary disruption to parts of its global operations. Most services have now ...

ALS Ltd. engages in the provision of analytical and testing services businesses and partnerships. It operates through the following segments: Life Sciences, Commodities, Industrial, and Other. The ...

We upgrade ALS Limited’s moat rating to narrow from no moat, and accordingly, our fair value estimate rises by 12% to AUD 10.20 per share. We estimate returns on invested capital, including goodwill, ...

Please be advised that today's conference is being recorded. I would now like to turn the call over to your first speaker today, Mr. Malcolm Deane, CEO and Managing Director. Thank you. Please go ...